Mymd Pharmaceuticals (NASDAQ:QCLS) Rating Increased to Sell at Wall Street Zen

by · The Markets Daily

Wall Street Zen upgraded shares of Mymd Pharmaceuticals (NASDAQ:QCLS – Free Report) from a strong sell rating to a sell rating in a research report report published on Saturday morning,Wall Street Zen reports.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Mymd Pharmaceuticals in a research note on Friday, August 7th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has an average rating of “Sell”.

Read Our Latest Stock Report on Mymd Pharmaceuticals

Mymd Pharmaceuticals Stock Up 0.4%

Shares of QCLS stock opened at $0.76 on Friday. The firm has a market cap of $6.25 million, a P/E ratio of -0.22 and a beta of 2.09. Mymd Pharmaceuticals has a 52 week low of $0.42 and a 52 week high of $8.94. The business’s 50 day moving average is $2.48.

Mymd Pharmaceuticals (NASDAQ:QCLS – Get Free Report) last announced its earnings results on Wednesday, August 12th. The company reported ($0.79) EPS for the quarter.

About Mymd Pharmaceuticals

(Get Free Report)

MyMD Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on developing therapies for diseases associated with aging, chronic inflammation and immune-system dysfunction. Its research has centered on small-molecule drug candidates intended to regulate immune and metabolic pathways.

The company’s lead development program has included MYMD-1, an orally administered investigational compound studied for potential applications involving autoimmune disease, chronic inflammation and age-related conditions.

See Also